{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00136903",
      "NCTIdAliasList": {
        "NCTIdAlias": [
          "NCT00476762"
        ]
      },
      "OrgStudyIdInfo": {
        "OrgStudyId": "260-261"
      },
      "Organization": {
        "OrgFullName": "Mesoblast, Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)",
      "OfficialTitle": "A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "April 27, 2005",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 28, 2006",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "July 14, 2008",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "August 25, 2005",
      "StudyFirstSubmitQCDate": "August 25, 2005",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "August 29, 2005",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "March 6, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 9, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Mesoblast, Inc.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "To establish the safety and efficacy of two dose levels of Ex-vivo Cultured Adult HumanMesenchymal Stem Cells (Prochymal) in subjects experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC) transplant.",
      "DetailedDescription": "Protocol 260 - Subjects will be randomized with equal probability to the treatment arms (2 million cells/kg of Prochymal or 8 million cells/kg of Prochymal) using a stratified block design. The stratification factor is acute GVHD grade. For the purpose of stratification, the GVHD grades are II and III-IV. Treatment with investigational agent was administered on study Days 1 and 4. Patients were followed for safety and efficacy until Day 28 after initiation of treatment with the investigational agent, or until withdrawal or death, whichever occurred first."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Graft Vs Host Disease"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Graft vs Host Disease",
          "GVHD",
          "Graft Versus Host Disease",
          "Bone marrow transplant",
          "Stem cells",
          "Mesenchymal stem cells",
          "Adult stem cells",
          "Leukemia",
          "Lymphoma"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "33",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Prochymal - 2 million cells",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Prochymal - 2 million cells/kg actual body weight, intravenously on study Days 1 and 4 plus daily methylprednisolone 2 mg/kg intravenously or prednisone 2.5 mg/kg orally. Subjects will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Prochymal - 2 million cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Prochymal - 8 million cells",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Prochymal - 8 million cells/kg actual body weight intravenously on study Days 1 and 4 plus daily methylprednisolone 2 mg/kg intravenously or prednisone 2.5 mg/kg orally. Subjects will also continue cyclosporine, tacrolimus, and/or MMF at full therapeutic doses",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Prochymal - 8 million cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Prochymal - 2 million cells",
            "InterventionDescription": "2 million cells/kg actual body weight, intravenously on study Days 1 and 4",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Prochymal - 2 million cells"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Ex-vivo Cultured Adult Human Mesenchymal Stem Cells",
                "human mesenchymal stem cells (hMSCs)"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Prochymal - 8 million cells",
            "InterventionDescription": "8 million cells/kg actual body weight intravenously on study Days 1 and 4",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Prochymal - 8 million cells"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Ex-vivo Cultured Adult Human Mesenchymal Stem Cells",
                "hMSCs"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Protocol 260 - Response by Day 28, also called Overall Response. Overall response. includes complete response (CR) and partial response (PR)",
            "PrimaryOutcomeTimeFrame": "28 Days"
          },
          {
            "PrimaryOutcomeMeasure": "Protocol 261- Patients were followed for 2 years for safety. The incidence rate of different adverse events among subjects treated with either dose of Prochymal® in the preceding study (Protocol No. 260).",
            "PrimaryOutcomeTimeFrame": "2 Years"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Protocol 260 - Partial Response or Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at Day 1,",
            "SecondaryOutcomeTimeFrame": "28 Days"
          },
          {
            "SecondaryOutcomeMeasure": "Protocol 260 - Time to best response of GVHD",
            "SecondaryOutcomeTimeFrame": "28 Days"
          },
          {
            "SecondaryOutcomeMeasure": "Protocol 260 - Time to improvement of GVHD in one or more organs",
            "SecondaryOutcomeTimeFrame": "28 Days"
          },
          {
            "SecondaryOutcomeMeasure": "Protocol 261 - Survival through study day 90",
            "SecondaryOutcomeTimeFrame": "90 Days"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Protocol 260 Inclusion Criteria:\n\nSubjects must be 18 to 70 years of age inclusive\nIf female and of child-bearing age, subjects must be non-pregnant, not breast feeding, and use adequate contraception. Males must use adequate contraception.\nSubject must have newly diagnosed, Grade II-IV acute GVHD requiring therapy. Biopsy for confirmation of GVHD is not mandatory, but is recommended when feasible. Enrollment should not be delayed awaiting biopsy results.\nSubject must have received either full or reduced intensity myeloablative regimens followed by an allogeneic hematopoietic stem cell transplant using bone marrow, peripheral blood stem cell, or cord blood, including donor lymphocyte infusion (DLI)\n\nSubjects must have minimal renal and hepatic function as defined by:\n\n* Calculated creatinine clearance (CLcr) of > 30 mL/min using the Cockroft-Gault equation\n\nSubject must be available for all specified assessments at the study site through study Day 28.\nSubjects must provide written informed consent and authorization for use and disclosure of protected health information (PHI).\n\nProtocol 260 Exclusion Criteria:\n\nSubject has received previous treatment for Grade II-IV acute GVHD (except as noted in criterion 2).\nSubject has been treated for GVHD with methylprednisolone, > 2mg/kg/day, for more than 72 hours prior to receiving Prochymal™\nSubject has uncontrolled alcohol or substance abuse within 6 months of randomization.\nSubject has received an investigational agent (not approved by FDA for marketed use in any indication) within 30 days of randomization. Subjects may not receive an investigational agent during the 28-day study period\nSubject has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the subject (e.g., uncontrolled infection, right heart failure, pulmonary hypertension, etc.)\nSubject has unstable arrhythmia\nSubject is unwilling to sign consent form for the long-term follow-up study, protocol No. 261\nSubject has a known allergy to bovine or porcine products.\nSubject had received transplant for a solid tumor disease.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Mahboob Rahman, MD",
            "OverallOfficialAffiliation": "Mesoblast, Inc.",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "St. Francis Hospital",
            "LocationCity": "Indianapolis",
            "LocationState": "Indiana",
            "LocationZip": "46237",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Kansas City Cancer Centers - BMT",
            "LocationCity": "Kansas City",
            "LocationState": "Missouri",
            "LocationZip": "64111",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "The Cancer Center at Hackensack University",
            "LocationCity": "Hackensack",
            "LocationState": "New Jersey",
            "LocationZip": "07601",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Roswell Park Cancer Institute",
            "LocationCity": "Buffalo",
            "LocationState": "New York",
            "LocationZip": "14263",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Mt. Sinai Hospital",
            "LocationCity": "New York",
            "LocationState": "New York",
            "LocationZip": "10029",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Rochester",
            "LocationCity": "Rochester",
            "LocationState": "New York",
            "LocationZip": "14642",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "New York Medical College",
            "LocationCity": "Valhalla",
            "LocationState": "New York",
            "LocationZip": "10595",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "MD Anderson Cancer Center",
            "LocationCity": "Houston",
            "LocationState": "Texas",
            "LocationZip": "77030",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Medical College of Wisconsin, FEC",
            "LocationCity": "Milwaukee",
            "LocationState": "Wisconsin",
            "LocationZip": "53226",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "11823036",
            "ReferenceType": "background",
            "ReferenceCitation": "Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002 Jan;30(1):42-8."
          },
          {
            "ReferencePMID": "10989188",
            "ReferenceType": "background",
            "ReferenceCitation": "Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000 Aug;28(8):875-84. Review."
          },
          {
            "ReferencePMID": "15846293",
            "ReferenceType": "background",
            "ReferenceCitation": "Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005 May;11(5):389-98."
          },
          {
            "ReferencePMID": "15121408",
            "ReferenceType": "background",
            "ReferenceCitation": "Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41."
          },
          {
            "ReferencePMID": "16040382",
            "ReferenceType": "background",
            "ReferenceCitation": "Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7(1):36-45. Review."
          },
          {
            "ReferencePMID": "19539211",
            "ReferenceType": "result",
            "ReferenceCitation": "Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Jul;15(7):804-11. doi: 10.1016/j.bbmt.2008.03.012."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Click here for more information on Prochymal for treatment of GVHD",
            "SeeAlsoLinkURL": "http://www.osiristx.com"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006086",
            "ConditionMeshTerm": "Graft vs Host Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10372",
            "ConditionBrowseLeafName": "Lymphoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10097",
            "ConditionBrowseLeafName": "Leukemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8341",
            "ConditionBrowseLeafName": "Graft vs Host Disease",
            "ConditionBrowseLeafAsFound": "Graft vs Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3543",
            "ConditionBrowseLeafName": "Lymphosarcoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2832",
            "ConditionBrowseLeafName": "Homologous Wasting Disease",
            "ConditionBrowseLeafAsFound": "Graft vs Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T170",
            "ConditionBrowseLeafName": "Acute Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "C000711674",
            "InterventionMeshTerm": "Remestemcel-l"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000893",
            "InterventionAncestorTerm": "Anti-Inflammatory Agents"
          },
          {
            "InterventionAncestorId": "D000000998",
            "InterventionAncestorTerm": "Antiviral Agents"
          },
          {
            "InterventionAncestorId": "D000000890",
            "InterventionAncestorTerm": "Anti-Infective Agents"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M13273",
            "InterventionBrowseLeafName": "Prednisone",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M11280",
            "InterventionBrowseLeafName": "Mycophenolic Acid",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M13272",
            "InterventionBrowseLeafName": "Prednisolone",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M1833",
            "InterventionBrowseLeafName": "Methylprednisolone Acetate",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M10901",
            "InterventionBrowseLeafName": "Methylprednisolone",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M10902",
            "InterventionBrowseLeafName": "Methylprednisolone Hemisuccinate",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M229437",
            "InterventionBrowseLeafName": "Prednisolone acetate",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M211896",
            "InterventionBrowseLeafName": "Prednisolone hemisuccinate",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M248768",
            "InterventionBrowseLeafName": "Prednisolone phosphate",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M18113",
            "InterventionBrowseLeafName": "Cyclosporine",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M5882",
            "InterventionBrowseLeafName": "Cyclosporins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M18102",
            "InterventionBrowseLeafName": "Tacrolimus",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M186752",
            "InterventionBrowseLeafName": "Remestemcel-l",
            "InterventionBrowseLeafAsFound": "0.65",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M3369",
            "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3466",
            "InterventionBrowseLeafName": "Antiviral Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3366",
            "InterventionBrowseLeafName": "Anti-Infective Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Infl",
            "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "AnEm",
            "InterventionBrowseBranchName": "Antiemetics"
          },
          {
            "InterventionBrowseBranchAbbrev": "NeuroAg",
            "InterventionBrowseBranchName": "Neuroprotective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Gast",
            "InterventionBrowseBranchName": "Gastrointestinal Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Derm",
            "InterventionBrowseBranchName": "Dermatologic Agents"
          }
        ]
      }
    }
  }
}